Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting
Completed
This is a Phase III trial designed to demonstrate that casopitant (GW679769) plus dexamethasone and ondansetron is more effective in the prevention of vomiting than dexamethasone and ondansetron alone following the administration of moderately emetogenic chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/06/2012
Locations: GSK Investigational Site, Corpus Christi, Texas +3 locations
Conditions: Vomiting, Nausea, Nausea and Vomiting, Chemotherapy-Induced
A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Anterior Uveitis
Terminated
This study will evaluate the safety and efficacy of an intravitreal implant of dexamethasone for the treatment of non-infectious anterior uveitis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2011
Locations: Not set, Dallas, Texas
Conditions: Anterior Uveitis
A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis
Completed
This study will evaluate the safety and efficacy of an intravitreal implant of dexamethasone for the treatment of non-infectious intermediate or posterior uveitis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2011
Locations: Not set, Dallas, Texas
Conditions: Intermediate Uveitis, Posterior Uveitis
Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Anterior Uveitis
Completed
The purpose of this study is to define a safe and effective dose of iontophoretic delivery of dexamethasone phosphate ophthalmic solution using the EyeGate® II Drug Delivery System in patients with non-infectious anterior segment uveitis.
Gender:
ALL
Ages:
Between 12 years and 85 years
Trial Updated:
08/27/2010
Locations: Texas Retina Associates, Dallas, Texas
Conditions: Uveitis, Anterior
Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma
Completed
Subjects who qualify for participation will receive lenalidomide with or without dexamethasone in 4 week cycles until disease progression is documented or lenalidomide becomes commercially available for the indication of multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2010
Locations: University of Texas Southwestern Medical Center, Dallas, Texas +1 locations
Conditions: Multiple Myeloma